- Oncimmune Holdings said its distributor for Israel, Best Medical Opinion, had received regulatory approval for the sale of the company's lung-cancer screening product.

On an age standardised basis, Israel's lung cancer mortality rate was 18.2%, making it one of the highest rates in the Middle East region.

'We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel,' chief executive Adam Hill said.

At 8:36am: [LON:ONC] Oncimmune Holdings Plc share price was 0p at 92.5p

Story provided by